- Home
- FCX vs TAK Comparison
FCX vs TAK Comparison
Compare FCX & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCX
- TAK
- Stock Information
- Founded
- FCX 1987
- TAK 1781
- Country
- FCX United States
- TAK Japan
- Employees
- FCX N/A
- TAK N/A
- Industry
- FCX Metal Mining
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- FCX Basic Materials
- TAK Health Care
- Exchange
- FCX Nasdaq
- TAK Nasdaq
- Market Cap
- FCX 56.0B
- TAK 47.5B
- IPO Year
- FCX N/A
- TAK N/A
- Fundamental
- Price
- FCX $41.47
- TAK $14.43
- Analyst Decision
- FCX Buy
- TAK
- Analyst Count
- FCX 13
- TAK 0
- Target Price
- FCX $49.85
- TAK N/A
- AVG Volume (30 Days)
- FCX 17.5M
- TAK 5.5M
- Earning Date
- FCX 07-23-2025
- TAK 07-30-2025
- Dividend Yield
- FCX 1.45%
- TAK 3.76%
- EPS Growth
- FCX N/A
- TAK N/A
- EPS
- FCX 1.32
- TAK 0.59
- Revenue
- FCX $25,820,000,000.00
- TAK $31,053,301,865.00
- Revenue This Year
- FCX $9.37
- TAK $0.47
- Revenue Next Year
- FCX $10.15
- TAK $0.80
- P/E Ratio
- FCX $31.42
- TAK $47.52
- Revenue Growth
- FCX 4.64
- TAK 1.52
- 52 Week Low
- FCX $27.66
- TAK $12.80
- 52 Week High
- FCX $52.61
- TAK $15.53
- Technical
- Relative Strength Index (RSI)
- FCX 45.87
- TAK 48.55
- Support Level
- FCX $39.60
- TAK $13.49
- Resistance Level
- FCX $40.60
- TAK $14.29
- Average True Range (ATR)
- FCX 1.50
- TAK 0.22
- MACD
- FCX -0.23
- TAK 0.04
- Stochastic Oscillator
- FCX 40.49
- TAK 68.25
About FCX Freeport-McMoRan Inc.
Freeport-McMoRan owns stakes in 10 copper mines, led by its 49% ownership of the Grasberg copper and gold operations in Indonesia, 55% of the Cerro Verde mine in Peru, and 72% of Morenci in Arizona. It sold around 1.2 million metric tons of copper (its share) in 2024, making it the one of the world's largest copper miners by volume. It also sold about 900,000 ounces of gold, mostly from Grasberg, and 70 million pounds of molybdenum. It had about 25 years of copper reserves at the end of December 2024. We expect it to sell similar amounts of copper midcycle in 2029, though we expect gold volumes to decline to about 650,000 ounces then due to falling production at Grasberg.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.